Navigation Links
Discovery demonstrates potential MS therapy could kill brain cells
Date:5/6/2011

Edmonton Researchers with the Faculty of Medicine & Dentistry at the University of Alberta have discovered that some "protective" T-cells can kill neurons. This finding is significant because a specific type of T-cell therapy is being touted in the medical community as a potential treatment for MS and other autoimmune conditions.

Dr. Fabrizio Giuliani and his post-doctoral fellow, Yohannes Haile, both from the Division of Neurology, collaborated on this research which was recently published in the Journal of Leukocyte Biology, a peer-reviewed medical journal.

"Using T-cells has been seen as a potential treatment for autoimmune diseases," says Dr. Giuliani. "But these cells that are supposed to be regulatory, when activated, they can kill. In our hands, at least, they were able to kill neurons. So this is very important. In MS literature, they were starting to talk about using the infusion of these cells as treatment. This area needs to be studied more before these cells are used as a therapy for MS patients."

The finding was serendipitous, says Giuliani.

"We were using some of the cells that we have described here as a control in our project. And then the T-cells did something interesting, something we weren't expecting. In fact, we were expecting the exact opposite response with these cells.

"We were looking at how a specific type of T-cell could prevent neuronal death and then we found out they were doing the killingThese are the best findings when you are expecting something different and then you observe an amazing phenomenon."

T-cells are very important their primary role is to attack foreign viruses or bacteria and to regulate or maintain immune system tolerance. However, when T-cell tolerance is disrupted, they can cause autoimmune diseases.

Researchers in the medical community have thought if they could carefully collect regulatory T-cells and inject them into patients with autoi
'/>"/>

Contact: Raquel Maurier
raquel.maurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Page: 1 2

Related biology news :

1. Worm discovery could help 1 billion people worldwide
2. New discovery could green up hundreds of everyday products
3. Discovery identifies elaborate G-protein network in plants
4. A chance discovery may revolutionize hydrogen production
5. A world first: The discovery of a common genetic cause of autism and epilepsy
6. Discovery of protein that alters nutrition of breast cancer cells
7. Missouri Botanical Garden makes rare discovery of plant genus
8. Discovery of a biochemical basis for broccolis cancer-fighting ability
9. Discovery of source of glycogen manufacturing errors sheds light on fatal disease
10. MU researchers believe discovery could lead to testing that displaces colonoscopies
11. Discovery of blood proteins that are red flags for ectopic pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... may soon be a boon to biofuels producers. The ... a surprisingly minimal repertoire of genes that it employs ... further improvements in enzymes customized for biofuels production. ... Biotechnology by a team of government, academic, and industry ...
... the public and the scientific community for access to ... copyright policy to allow authors to retain the rights ... which became effective May 1, applies to all three ... The Journal of Experimental Medicine and The Journal of ...
... (May 2, 2008)As the westernization of India accelerates, tobacco advertising ... urban Indian children as young as 11, according to a ... Public Health. , The study, Associations Between Tobacco Marketing ... the May/June issue of the American Journal of Health Behavior. ...
Cached Biology News:Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 2Lean and mean biomass-degrading fungus reveals capabilities for improved biofuel production 3Rockefeller University Press allows authors to retain copyright to their published work 2UT researchers find link between advertising and increased tobacco use among India's youth 2UT researchers find link between advertising and increased tobacco use among India's youth 3
(Date:7/30/2015)... 30, 2015 According to a ... Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, ... Clinical Trial), by End Users - Global Forecast to ... to reach USD 2,107.99 million by 2020 from USD ... Browse more than 75 ...
(Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 15 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... sale of shares of convertible preferred stock pursuant to a ... proceeds of approximately $2 million. The preferred stock is convertible ... the investor at a price of $0.1105 per share. , ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... endocrine therapy and oncology, today reported that patient follow-up ... Phase 3 program in benign prostatic hyperplasia (BPH) with ... be completed at the end of this week. Therefore, ...
... Inc., an award-winning developer of Microfluidics and Live ... its cellTRAY Imaging System and cellTRAY Fluidics System ... Imaging and Fluidics Systems provide solutions to a ... reproductive technology (ART), stem cell research, and cryobiology, ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems 2
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Request Info...
...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: